Today: 25 January 2026
Subscribe

Marcin Frąckiewicz

CEO of TS2 Space and founder of TS2.tech. Expert in satellites, telecommunications, and emerging technologies, covering trends in space, AI, and connectivity.

Intellia Therapeutics (NTLA) Soars on CRISPR Breakthroughs – Latest Updates & Stock Outlook

Why Intellia Therapeutics’ Stock Could Be a Gene‑Editing Goldmine in 2025 – Deep Dive into NTLA’s Prospects

Quick Facts (as of 8 Oct 2025) Recent Performance and News Phase 1 data fuels rally Intellia’s October rally was triggered by longer‑term Phase 1 results for nexiguran ziclumeran (nex‑z), an in‑vivo CRISPR therapy for transthyretin (ATTR) amyloidosis. A GlobeNewswire release (Sept 25 2025) reported that a single dose produced a rapid, deep and durable reduction of serum TTR levels—mean reduction 92 % at 24 months and 90 %…
8 October 2025
···
CRISPR Therapeutics Stock Update (Oct 8 2025): Why Gene‑Editing Bulls See Big Upside

CRISPR Therapeutics Stock Update (Oct 8 2025): Why Gene‑Editing Bulls See Big Upside

Stock Price, Volume and Sentiment According to AAII, CRSP’s share price on 8 Oct 2025 closed at $77.727, up 10.06 % from the previous close. The stock traded between $70.77 and $78.38 that day and has risen ~20 % during October. Over the prior year the share price ranged from $30.04 to $73.95, and year‑to‑date performance stood at +97.5 %. Trading volume on INDmoney’s quote…
8 October 2025
···
Intellia Therapeutics (NTLA) Soars on CRISPR Breakthroughs – Latest Updates & Stock Outlook

Intellia Therapeutics (NTLA) Soars on CRISPR Breakthroughs – Latest Updates & Stock Outlook

Intellia at a Glance: CRISPR Trailblazer in 2025 Intellia Therapeutics, Inc. (NASDAQ: NTLA) is a clinical-stage biotechnology company at the forefront of CRISPRgene editing medicines. Headquartered in Cambridge, MA, Intellia was one of the first companies to harness CRISPR-Cas9 technology to develop potential in vivo therapies – treatments delivered directly into the body to edit genes inside patients’ cells. In fact, Intellia reported the first-ever…
8 October 2025
···
TSMC Stock Soars on AI Boom: Record Highs, Big Ambitions & Geopolitical Risks (Oct 2025 Update)

TSMC Stock Soars on AI Boom: Record Highs, Big Ambitions & Geopolitical Risks (Oct 2025 Update)

Overview: TSMC’s Business and Recent Performance Taiwan Semiconductor Manufacturing Co. (TSMC) is the world’s largest contract chipmaker (pure-play foundry), producing advanced semiconductors for clients like Apple, NVIDIA, AMD, and many others Com ts2.tech. Rather than selling its own branded chips, TSMC builds chips to order, focusing on cutting-edge manufacturing processes. This model has made TSMC a pillar of global tech supply chains and…
8 October 2025
····
Apple Stock Hits New Heights: iPhone 17 Supercycle, Analyst Split, and 2025 Outlook Revealed

Apple Stock Hits New Heights: iPhone 17 Supercycle, Analyst Split, and 2025 Outlook Revealed

Overview: Apple Inc. and Recent Performance Apple Inc. – the world’s largest company by market capitalization – has had a mixed 2025 so far. With a market cap around $3.8 trillion ts2.tech, Apple’s size means even modest growth is hard-fought. Year-to-date, AAPL stock is roughly flat (+~2%), underperforming the broader tech sector ts2.tech. This muted performance comes despite Apple achieving record financial results in 2025 (its June…
8 October 2025
····
Cisco’s $2B AI Windfall: New Tech, Stock Surge & What’s Next for CSCO

Cisco’s $2B AI Windfall: New Tech, Stock Surge & What’s Next for CSCO

Cisco’s Business Model & Market Position Cisco Systems is best known as the world’s largest vendor of networking hardware and software, powering much of the internet’s infrastructure. The company’s business model centers on selling network equipment (like routers, switches, and wireless access points), along with security solutions, collaboration tools (e.g. Webex conferencing gear/software), and observability software (monitoring and analytics, bolstered by its 2024 acquisition of Splunk). In addition,…
8 October 2025
···
UnitedHealth Group Stock Surges Amid Analyst Upgrades: Is Wall Street Turning Bullish on UNH in 2025?

UnitedHealth Group Stock Surges Amid Analyst Upgrades: Is Wall Street Turning Bullish on UNH in 2025?

Current Stock Price and Performance (Oct 8 2025) UnitedHealth Group’s share price has been volatile in 2025. On 8 Oct 2025 the stock closed around $372—IndMoney quoted $372.93 while Investing.com listed $372.64 Indmoney Investing. Reuters reported that the last trade was $371.46, up 2.15 % from the previous day Reuters. The wide 52‑week range ($234.60‑$630.73) highlights the enormous drawdown from April’s peak and underscores the…
8 October 2025
···
Reddit’s Stock Explodes! 78% Revenue Surge, Google AI Deal Talks & 70% Rally 🔥

Reddit’s Rollercoaster: How Booming Ads, AI Deals and Political Scrutiny Could Shock RDDT Investors

Key Facts (as of 8 Oct 2025) Item Detail Sources Current stock price Reddit’s Class A shares traded around $199.54 at 11:58 AM EDT on 8 Oct 2025 with an intraday high of $206.22 and low of $195.01; the official investor‑relations site notes a 52‑week high of $282.95 and low of $69.30 Redditinc. Reddit investor relations Analyst consensus Across 25‑28 analysts the consensus rating is “moderate/buy”.…
8 October 2025
···
Palo Alto Networks’ AI-Fueled Surge: Stock Soars on Cybersecurity Boom, Bold Forecasts & Big Deals

Palo Alto Networks’ AI-Fueled Surge: Stock Soars on Cybersecurity Boom, Bold Forecasts & Big Deals

Sources: Palo Alto Networks and CyberArk deal coverage – Reuters Reuters Reuters; Q4 2025 earnings and guidance – Reuters Reuters, Futurum Futurumgroup Futurumgroup; Analyst ratings and price targets – StockAnalysis Stockanalysis Stockanalysis; Competitive landscape – Bullish Bears Bullishbears Bullishbears; Unit 42 threat intel news – ts2.tech ts2.tech; Expert quotes – Reuters Reuters, Breakingviews Reuters; Stock performance data – Yahoo/Benzinga Hotcandlestick.…
8 October 2025
····
Confluent, Inc. (CFLT) – Will a Real‑Time Data Pioneer Become a Takeover Target? (October 8 2025)

Unraveling Confluent (CFLT) Stock: Latest Price, AI‑Driven Buzz & What Experts Say

Current Stock Price & Recent Performance (as of 8 Oct 2025) Date Open High Low Close Daily Change Notes 8 Oct 2025 $23.72 $24.07 $21.98 $22.84 −10.18 % Stock decline amid deal speculation and market volatility Stockanalysis. 7 Oct 2025 $21.33 $21.33 $20.12 $20.73 −2.50 % Day after Reuters’ sale‑rumor report; shares closed near weekly low Stockanalysis. 6 Oct 2025 $20.50 $21.49 $20.23 $21.26 +7.36 % Stock rallied following takeover rumors…
8 October 2025
···
AI Drug Discovery Darling? Recursion Pharma (RXRX) Stock’s Wild Ride in 2025

AI Drug Discovery Darling? Recursion Pharma (RXRX) Stock’s Wild Ride in 2025

Introduction: A New Kind of Biotech Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX) is redefining drug discovery by combining cutting-edge biology and data science. Based in Salt Lake City, this “TechBio” pioneer uses automation, massive datasets and machine learning to identify new therapies faster than traditional labs Directorstalkinterviews Nasdaq. Its mission – “to decode biology to radically improve lives” – has attracted…
8 October 2025
···
AiRWA (YYAI) Stock Soars 44% on $100M Crypto Pivot – Expert Insights

AiRWA (YYAI) Stock Soars 44% on $100M Crypto Pivot – Expert Insights

Company Background and Pivot AiRWA Inc (formerly Connexa Sports) built its name in sports technology. Its flagship was the Slinger Bag – a portable, AI-enhanced tennis ball machine – and it acquired analytics firms like Gameface AI and PlaySight to create a “Watch–Play–Learn” sports-tech ecosystem ts2.tech. Under CEO Mike Ballardie, Connexa integrated AI vision systems and smart sensors to provide…
8 October 2025
···
1 … 399 400 401 402 403 … 584

Stock Market Today

  • FTAI Aviation Shares Surge Amid Valuation Concerns - Overvalued by 115%
    January 25, 2026, 11:36 AM EST. FTAI Aviation's share price closed at $292.10, soaring over 224% in the past year, prompting investors to scrutinize its valuation. Despite strong price gains, a Discounted Cash Flow (DCF) model estimates the stock's intrinsic value at $135.47, suggesting the shares are overvalued by 115.6%. The company reported a free cash flow loss of about $1.45 billion over the past twelve months, while analysts forecast positive cash flows up to 2029. FTAI's rich valuation raises questions amid a lack of new earnings guidance. Investors weigh the company's position in aviation assets against long-term sector demand. FTAI Aviation scores 0 out of 6 on valuation checks, signaling caution for those considering entry post recent gains.
Go toTop